Page 9 - Bharat Biotech

Bharat Biotech injects pace into Covid-19 vaccine Covaxin supply

Constraints on the availability of India's first indigenous Covid-19 vaccine could end soon

Bharat Biotech likely to start manufacturing Covaxin at Pune plant soon

Animal vaccine maker Hester Biosciences, on the other hand, is setting up a greenfield BSL-3 facility in Gujarat to make Covaxin

Paediatric Covaxin: Bharat Biotech completes phase 2/3 trials of vaccine

Bharat Biotech has completed Phase 2/3 trials of Covid-19 vaccine, Covaxin for use in children under 18 years of age and is expected to submit the data by next week to the DCGI

WHO Experts' Group to take a call on EUL for Covaxin on October 6

The Strategic Advisory Group of Experts on Immunization of the WHO would be meeting in October to make its recommendations on Bharat Biotech's COVID-19 vaccine Covaxin on Emergency Use Listing

WHO emergency use authorisation to Covaxin delayed till October 5

World Health Organisation's (WHO) approval for the emergency use authorisation to COVID-19 vaccine Covaxin, developed by the Hyderabad-based Bharat Biotech, is likely to be delayed till October 5.

Bharat Biotech awaits feedback from WHO for Covaxin emergency use

: Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine Covaxin to the World health organisation for Emergency Use Listing (EUL) and is awaiting feedback from the global health watchdog. The WHO is currently reviewing the data submitted by the vaccine maker and the date for a decision on the jab is yet "to be confirmed," according to the update available on WHO website. "#COVAXIN clinical trial data was fully compiled & available in June 2021. All Data submitted for Emergency Use Listing (EUL) Application to World Health Organization in early July. We have responded to any clarifications sought by #WHO and are awaiting further feedback," Bharat Biotech tweeted. As a responsible manufacturer with past approvals for its other vaccines, the company said it would not find it appropriate to speculate or comment on approval process and its timelines, it further said. "We are continuing to work diligently on obtaining WHO EUL at the earliest, the .

Phase 2 trials begin for India's first intranasal vaccine against Covid-19

The phase 2 trials of India's first intranasal vaccine against Covid, being developed by Bharat Biotech in collaboration with Washington University School of Medicine, have commenced in Kanpur

First commercial batch of Covaxin released from Bharat Biotech's new plant

The first commercial batch of Covaxin was released on Sunday from the new plant of Bharat Biotech at Ankleshwar in Gujarat's Bharuch district by Union Health Minister Mansukh Mandaviya

Bharat Biotech scouts international Covid-19 vaccine partners

Bharat Biotech said it was exploring opportunities with its international partners who have expertise in commercial-scale manufacturing of inactivated viral vaccines.

Johnson & Johnson seeks nod for Covid vaccine trial on adolescents

To achieve herd immunity, studies have to be done on children, pharma major says

Bharat Biotech's nasal Covid-19 vaccine advances into next stage of trials

Early stage trials of the vaccine candidate, BBV154, has been completed in subjects aged 18 to 60 years, and the doses were found to be well tolerated

Serum chairman Cyrus Poonawalla against using cocktail of Covid vaccines

Serum Institute of India (SII) chairman Dr Cyrus Poonawalla on Friday said he was not in favour of administering two different coronavirus vaccines for better efficacy. Poonawalla, whose firm makes the Covishield vaccine, was speaking to reporters after receiving the Lokmanya Tilak National Award here. "I am against the mixing of two different vaccines. There is no need to mix two different vaccines," he said, when asked about a recent ICMR study that a cocktail of Covishield and Covaxin could generate better immunity. "If cocktail vaccines are administered and if the result is not good, then SII may say that another vaccine was not good, vice versa, the other company might say that since you mixed Serum's vaccine, it did not give desired results," Poonawalla said. The efficacy of this approach has not been proven in field trials involving thousands of participants, he added. A study by the Indian Council of Medical Research involving 98 people, 18 of whom had inadvertently ...

Indian Immunologicals to make drug material for 10 mn Covaxin doses a month

IIL has repurposed its manufacturing unit in Hyderabad, procured key raw materials and consumables apart from equipment at 'breakneck' speed; production commenced in July

PSU receives loan license to supply Bharat Biotech's Covaxin drug substance

PSU Indian Immunologicals Limited has received a loan license from drug regulator CDSCO for supplying to Bharat Biotech Covaxin drug substance produced at its repurposed facility, DBT said on Friday

Bharat Biotech's intranasal vaccine gets regulator nod for Phase 2/3 trials

It is the first nasal vaccine in the country that has received the regulatory approval for late-stage clinical trials

Covid-19 pandemic: Bharat Biotech's Covaxin ready for dispatch at new plant

The doses are ready to be dispatched to the Central Drugs Laboratory in Kasauli for quality and sterility inspection this month

Mandaviya meets WHO chief scientist, discusses health body nod for Covaxin

Mandaviya on Thursday met WHO Chief Scientist Dr Soumya Swaminathan and held discussions over the global health body's approval for Bharat Biotech's COVID-19 vaccine Covaxin

Govt okays Bharat Biotech's Ankleshwar plant to produce Covaxin: Minister

Union minister Mansukh Mandaviya on Tuesday said the government has given approval to Bharat Biotech's Ankleshwar-based manufacturing plant to produce COVID-19 vaccine Covaxin. "Govt of India approves vaccine manufacturing facility for production of @BharatBiotech's #Covaxin in Ankleshwar, Gujarat," Mandaviya tweeted. The approval would help increase availability of COVID-19 vaccines in the country, he added. "Following PM @NarendraModi ji's vision of #SabkoVaccineMuftVaccine, this will increase vaccine availability & accelerate the world's largest vaccine drive," the minister who heads both Chemicals and Fertilisers and Health ministries noted. In May this year, Bharat Biotech had announced that it plans to produce an additional 200 million doses of Covaxin at its subsidiary's Ankleshwar-based facility. The Hyderabad-based firm had noted that it would utilise the manufacturing plant of its wholly-owned unit - Chiron Behring, to add another 200 million doses of Covaxin.

Mixing Covaxin and Covishield safe, gives better immune response: ICMR

The study was conducted on 18 individuals who inadvertently received Covishield as first jab and Covaxin as second in UP at a gap of six weeks

Covishield-Covaxin combination works better than 2 doses of same jab: ICMR

Study also found that the combination was safe and adverse effects were found to be similar when compared to the same-dose regimen